Author:
Santana Dias Mariana,Guedes de Araujo Victor,Lani-Louzada Rafael,Linden Rafael,Toledo Ribas Vinicius,Petrs-Silva Hilda
Abstract
Glaucoma is a chronic and multifactorial neurodegenerative disease marked by structural damage to the optic nerve with axonal loss, progressive retinal ganglion cell degeneration, and optic disc excavation. Both high intraocular pressure and aging are important risk factors, but not essential to the progression of glaucomatous neurodegeneration. Current treatments are based on controlling intraocular pressure, which is not always effective in avoiding the progression of visual loss. In this sense, novel therapeutic strategies to glaucoma should aim to promote the neuroprotection of both the cell soma of retinal ganglion cells and the axons of the optic nerve. Gene therapy is a new therapeutical approach to glaucoma with a great capacity to overcome neurodegeneration. It consists of the transfer of exogenous genetic material to target cells with a therapeutic purpose. Gene therapy strategies for glaucoma include both the neuroprotection aiming to prevent cell soma and axonal loss and the regeneration of optic nerve axons. In this chapter, we review the most promising current gene therapies for glaucoma that address the various aspects of glaucoma pathology. We also discuss the potential of combining neuroprotective and regenerative strategies to reach a synergic effect for the treatment of glaucoma.
Reference100 articles.
1. WHO - World Health Organization. Global data on visual impairment [Internet]. 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment [Accessed: December 13, 2021]
2. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081-2090. DOI: 10.1016/j.ophtha.2014.05.013
3. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: A review. Journal of the American Medical Association. 2014;311(18):1901-1911. DOI: 10.1001/jama.2014.3192
4. Killer HE, Pircher A. Normal tension glaucoma: Review of current understanding and mechanisms of the pathogenesis. Eye (London, England). 2018;32(5):924-930. DOI: 10.1038/s41433-018-0042-2
5. Meier-Gibbons F, Berlin MS, Töteberg-Harms M. Influence of new treatment modalities on adherence in glaucoma. Current Opinion in Ophthalmology. 2019;30(2):104-109. DOI: 10.1097/ICU.0000000000000551